• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:MDMA)

0.1400 -0.0100 (-6.67%)
Streaming Delayed Price Updated: 3:57 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 79,019
Open 0.1450
Bid (Size) 0.1400 (64,500)
Ask (Size) 0.1500 (263,000)
Prev. Close 0.1500
Today's Range 0.1400 - 0.1500
52wk Range 0.0850 - 0.1950
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
July 21, 2026
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
May 13, 2026
From PharmAla Biotech
Via GlobeNewswire

Performance

YTD
+33.3%
+33.3%
1 Month
-3.4%
-3.4%
3 Month
-6.7%
-6.7%
6 Month
+40.0%
+40.0%
1 Year
+3.7%
+3.7%

More News

Read More
News headline image
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
April 27, 2026
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
April 20, 2026
From PharmAla Biotech
Via GlobeNewswire
News headline image
Cortexa Advances Commercialisation of MDMA Supply in Australia
March 23, 2026
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research
January 08, 2026
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance
December 15, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
Small Cap Growth Virtual Investor Conference Agenda Announced for October 16th
October 17, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Small Cap Growth Virtual Investor Conference Agenda Announced for October 16th
October 14, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
PharmAla Completes Shipment of LaNeo™ MDMA to Johns Hopkins
October 02, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Completes Shipment of LaNeo™ MDMA to Yale University, Provides Investor Update
June 03, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Contracts with Partner to Act as US Distributor
March 24, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
February 27, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
February 06, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
January 20, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
October 21, 2024
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024
From PharmAla Biotech
Via GlobeNewswire
News headline image
Canadian Biotech Duo Hits Psilocybin Extraction Milestone For API Development At Scale ↗
May 29, 2024
Via Benzinga
News headline image
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
April 05, 2024
From PharmAla Biotech
Via GlobeNewswire
News headline image
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
March 27, 2024
From PharmAla Biotech
Via GlobeNewswire
News headline image
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
March 20, 2024
From PharmAla Biotech
Via GlobeNewswire
News headline image
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
March 18, 2024
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
January 24, 2024
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
January 08, 2024
From PharmAla Biotech
Via GlobeNewswire

Frequently Asked Questions

Is MDMA publicly traded?
Yes, MDMA is publicly traded.
What exchange does MDMA trade on?
MDMA trades on the Canadian Securities Exchange
What is the ticker symbol for MDMA?
The ticker symbol for MDMA is MDMA on the Canadian Securities Exchange
What is the current price of MDMA?
The current price of MDMA is 0.1400
When was MDMA last traded?
The last trade of MDMA was at 08/07/26 03:57 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap